Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209,796 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
Harding JJ, Zhu AX, Bauer TM, Choueiri TK, Drilon A, Voss MH, Fuchs CS, Abou-Alfa GK, Wijayawardana SR, Wang XA, Moser BA, Uruñuela A, Wacheck V, Bendell JC. Harding JJ, et al. Among authors: wang xa. Clin Cancer Res. 2019 Sep 1;25(17):5202-5211. doi: 10.1158/1078-0432.CCR-18-4010. Epub 2019 May 29. Clin Cancer Res. 2019. PMID: 31142504 Clinical Trial.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Bendell JC, Bischoff HG, Hwang J, Reinhardt HC, Zander T, Wang X, Hynes S, Pitou C, Campbell R, Iversen P, Farrington DL, Bell-McGuinn K, Thomas M. Bendell JC, et al. Among authors: wang x. Invest New Drugs. 2020 Aug;38(4):1145-1155. doi: 10.1007/s10637-019-00873-6. Epub 2019 Nov 9. Invest New Drugs. 2020. PMID: 31707688 Clinical Trial.
Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Hong DS, Moore KN, Bendell JC, Karp DD, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP, Ding Y, Capen A, Wang X, Bence Lin A, Patel MR. Hong DS, et al. Among authors: wang x, wang js. Clin Cancer Res. 2021 Apr 1;27(7):1864-1874. doi: 10.1158/1078-0432.CCR-20-3242. Epub 2021 Jan 25. Clin Cancer Res. 2021. PMID: 33495309 Clinical Trial.
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
Byers LA, Navarro A, Schaefer E, Johnson M, Özgüroğlu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M. Byers LA, et al. Among authors: wang x. Clin Lung Cancer. 2021 Nov;22(6):531-540. doi: 10.1016/j.cllc.2021.04.005. Epub 2021 Apr 24. Clin Lung Cancer. 2021. PMID: 34034991 Free article. Clinical Trial.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ, Olszanski AJ, Weigang-Köhler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E. Faivre SJ, et al. Among authors: wang x. Invest New Drugs. 2015 Dec;33(6):1206-16. doi: 10.1007/s10637-015-0286-7. Epub 2015 Sep 16. Invest New Drugs. 2015. PMID: 26377590 Clinical Trial.
209,796 results
You have reached the last available page of results. Please see the User Guide for more information.